NPI: 1699013565 · MOUNTAIN HOME, ID 83647 · Critical Access Hospital · NPI assigned 01/28/2013
Authorized official FOWLER, KATHRYN controls 18+ related entities in our dataset. Read more
| Authorized Official | FOWLER, KATHRYN (SENIOR VP, CFO) |
| Parent Organization | ST LUKES HEALTH SYSTEM LTD |
| NPI Enumeration Date | 01/28/2013 |
Other providers sharing the same authorized official: FOWLER, KATHRYN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 23,531 | $314K |
| 2019 | 22,932 | $274K |
| 2020 | 12,439 | $150K |
| 2021 | 3,495 | $35K |
| 2022 | 4,510 | $60K |
| 2023 | 5,169 | $79K |
| 2024 | 2,220 | $29K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 1,311 | 1,125 | $149K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 578 | 548 | $96K |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 1,103 | 941 | $94K |
| 80053 | Comprehensive metabolic panel | 7,008 | 5,907 | $55K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 8,739 | 7,132 | $51K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 738 | 574 | $35K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 422 | 393 | $32K |
| 70450 | Computed tomography, head or brain; without contrast material | 511 | 482 | $22K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 559 | 500 | $20K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 559 | 500 | $20K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1,221 | 965 | $20K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 142 | 114 | $18K |
| 84443 | Thyroid stimulating hormone (TSH) | 1,215 | 1,191 | $16K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 230 | 206 | $15K |
| 81001 | 4,441 | 3,873 | $14K | |
| 84484 | 1,908 | 1,535 | $14K | |
| 36415 | Collection of venous blood by venipuncture | 6,805 | 5,430 | $14K |
| 71046 | Radiologic examination, chest; 2 views | 1,073 | 1,032 | $13K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 727 | 670 | $13K |
| 83690 | 1,869 | 1,637 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1,812 | 1,635 | $12K |
| J7050 | Infusion, normal saline solution, 250 cc | 2,650 | 1,886 | $11K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1,930 | 1,689 | $10K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 143 | 138 | $9K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 656 | 637 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1,351 | 1,155 | $9K |
| 71045 | Radiologic examination, chest; single view | 1,323 | 1,181 | $8K |
| 84702 | 455 | 332 | $7K | |
| 87081 | 942 | 924 | $6K | |
| 87077 | 745 | 706 | $6K | |
| 81025 | 856 | 799 | $6K | |
| 80061 | Lipid panel | 730 | 715 | $6K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 998 | 825 | $6K |
| 82962 | 3,767 | 683 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 274 | 269 | $6K |
| 83605 | 545 | 456 | $6K | |
| 76830 | Ultrasound, transvaginal | 83 | 81 | $5K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 874 | 752 | $5K |
| 84439 | 651 | 638 | $5K | |
| 80306 | 281 | 268 | $4K | |
| 83880 | 173 | 157 | $4K | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 434 | 378 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | 744 | 721 | $4K |
| 87186 | 427 | 407 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 59 | 58 | $3K |
| 85379 | 288 | 264 | $3K | |
| 87040 | 218 | 153 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 939 | 855 | $3K |
| 86140 | 370 | 327 | $2K | |
| 84481 | 180 | 177 | $2K | |
| J2704 | Injection, propofol, 10 mg | 86 | 76 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,049 | 925 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 51 | 50 | $2K |
| 85610 | 489 | 338 | $2K | |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 342 | 295 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | 44 | 41 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 27 | 27 | $2K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 12 | 12 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 151 | 131 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 62 | 62 | $2K |
| 73630 | 111 | 103 | $1K | |
| 86850 | 183 | 175 | $1K | |
| 74018 | 69 | 64 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 515 | 298 | $1K |
| 73610 | 72 | 67 | $1K | |
| 87420 | 79 | 79 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 13 | 13 | $1K |
| 86901 | 306 | 290 | $958.48 | |
| 73564 | 36 | 36 | $814.66 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 290 | 244 | $801.40 |
| 86900 | 247 | 234 | $770.46 | |
| 73110 | 40 | 38 | $726.20 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 191 | 149 | $716.73 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 17 | 17 | $699.92 |
| 85652 | 133 | 117 | $699.72 | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | 13 | 12 | $663.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 61 | 58 | $641.34 |
| 86593 | 132 | 130 | $587.98 | |
| 36416 | 209 | 155 | $579.65 | |
| 86703 | 43 | 42 | $578.73 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 46 | 38 | $560.97 |
| 82728 | 50 | 49 | $530.25 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 163 | 148 | $500.83 |
| 84703 | 55 | 55 | $483.65 | |
| 82607 | 37 | 37 | $476.36 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 44 | 39 | $472.05 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 306 | 296 | $458.30 |
| 87210 | 96 | 94 | $447.90 | |
| 83735 | 80 | 77 | $402.19 | |
| 96361 | Intravenous infusion, hydration; each additional hour | 32 | 27 | $402.18 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 61 | 49 | $262.07 |
| 87340 | 28 | 27 | $252.54 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 14 | 12 | $243.26 |
| 86803 | 13 | 13 | $198.28 | |
| 90715 | 13 | 13 | $185.70 | |
| 86762 | 13 | 12 | $143.91 | |
| 72100 | 12 | 12 | $136.22 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 13 | 13 | $128.59 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 158 | 126 | $104.78 |
| 81002 | 44 | 38 | $88.54 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 627 | 579 | $70.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 13 | 12 | $60.90 |
| G0008 | Administration of influenza virus vaccine | 54 | 52 | $45.07 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 74 | 68 | $37.50 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 667 | 553 | $0.03 |
| A9270 | Non-covered item or service | 376 | 220 | $0.00 |
| 80050 | General health panel | 35 | 33 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 42 | 39 | $-7.43 |